Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hyloris Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group
Details : Maxigesic IV (a unique combination of 1000 mg paracetamol and 300 mg ibuprofen solution for infusion) is a novel, patented, non-opioid pain treatment, and is being commercialised by Hyloris’ partner AFT Pharmaceuticals.
Product Name : Maxigesic IV
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 24, 2021
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hyloris Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement